| Year |
Citation |
Score |
| 2023 |
Li X, Sale M, Nieforth K, Bigos KL, Craig J, Wang F, Feng K, Hu M, Bies R, Zhao L. pyDarwin: A Machine Learning Enhanced Automated Nonlinear Mixed-effect Model Selection Toolbox. Clinical Pharmacology and Therapeutics. PMID 38037471 DOI: 10.1002/cpt.3114 |
0.679 |
|
| 2022 |
Yu Y, Bigos KL, Marzinke MA, Landovitz RJ, McCauley M, Ford S, Hendrix CW, Bies RR, Weld ED. A Population Pharmacokinetic Model Based on HPTN 077 of Long-acting Injectable Cabotegravir for HIV PrEP. British Journal of Clinical Pharmacology. PMID 35949044 DOI: 10.1111/bcp.15477 |
0.682 |
|
| 2022 |
Ismail M, Straubinger T, Uchida H, Graff-Guerrero A, Nakajima S, Suzuki T, Caravaggio F, Gerretsen P, Mamo D, Mulsant BH, Pollock BG, Bies R. "MAP Bayesian modeling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients". British Journal of Clinical Pharmacology. PMID 35112390 DOI: 10.1111/bcp.15260 |
0.414 |
|
| 2021 |
Kish SJ, O'Leary G, Mamelak M, McCluskey T, Warsh JJ, Shapiro C, Bies R, Yu Y, Pollock B, Tong J, Boileau I. Does sodium oxybate inhibit brain dopamine release in humans? An exploratory neuroimaging study. Human Psychopharmacology. e2791. PMID 33899252 DOI: 10.1002/hup.2791 |
0.335 |
|
| 2020 |
Reeves S, Bertrand J, Uchida H, Yoshida K, Otani Y, Ozer M, Liu KY, Bramon E, Bies R, Pollock BG, Howard R. Towards safer risperidone prescribing in Alzheimer's disease. The British Journal of Psychiatry : the Journal of Mental Science. 1-8. PMID 33176899 DOI: 10.1192/bjp.2020.225 |
0.396 |
|
| 2019 |
Straubinger T, Kay K, Bies R. Modeling HIV Pre-Exposure Prophylaxis. Frontiers in Pharmacology. 10: 1514. PMID 32082142 DOI: 10.3389/Fphar.2019.01514 |
0.302 |
|
| 2019 |
Koizumi T, Bies R, Suzuki T, Pollock B, Mimura M, Uchida H. Fluctuations in hallucinatory experiences within a day in relation to dopamine D2 receptor blockade with antipsychotics in patients with schizophrenia European Neuropsychopharmacology. 29: S134-S135. DOI: 10.1016/j.euroneuro.2018.11.246 |
0.364 |
|
| 2016 |
Sakurai H, Suzuki T, Bies RR, Pollock BG, Mimura M, Kapur S, Uchida H. Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. The Journal of Clinical Psychiatry. 77: 1381-1390. PMID 27788310 DOI: 10.4088/JCP.15m10490 |
0.421 |
|
| 2016 |
Ho T, Pollock BG, Mulsant BH, Schantz O, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Drye LT, Munro CA, Shade DM, Lyketsos C, Bies R. R-and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. British Journal of Clinical Pharmacology. PMID 27145364 DOI: 10.1111/Bcp.12997 |
0.416 |
|
| 2016 |
Lee J, Bies R, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Quantifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approach. The Journal of Clinical Psychiatry. PMID 27136679 DOI: 10.4088/Jcp.14M09714 |
0.313 |
|
| 2016 |
Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. Human Psychopharmacology. PMID 27060853 DOI: 10.1002/hup.2532 |
0.403 |
|
| 2015 |
Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Shade DM, Lyketsos CG. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26611790 DOI: 10.1007/S10928-015-9457-6 |
0.39 |
|
| 2015 |
Tsuboi T, Bies RR, Suzuki T, Takeuchi H, Nakajima S, Graff-Guerrero A, Mamo DC, Caravaggio F, Plitman E, Mimura M, Pollock BG, Uchida H. Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study. Pharmacopsychiatry. PMID 26506574 DOI: 10.1055/S-0035-1565070 |
0.439 |
|
| 2015 |
Lee J, Bies R, Bhaloo A, Powell V, Remington G. Clozapine and anemia: a 2-year follow-up study. The Journal of Clinical Psychiatry. PMID 26301364 DOI: 10.4088/Jcp.14M09143 |
0.309 |
|
| 2015 |
Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Mamo DC, Graff-Guerrero A. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. Schizophrenia Bulletin. PMID 26221049 DOI: 10.1093/Schbul/Sbv106 |
0.409 |
|
| 2015 |
Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Clinical Pharmacokinetics. PMID 25971243 DOI: 10.1007/s40262-015-0275-1 |
0.42 |
|
| 2015 |
Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. Schizophrenia Research. 164: 149-54. PMID 25864950 DOI: 10.1016/J.Schres.2015.03.025 |
0.402 |
|
| 2015 |
Isbister GK, Bies R. Pharmacometrics: so much mathematics and why planes achieve their destinations with almost perfect results …. British Journal of Clinical Pharmacology. 79: 1-3. PMID 25223922 DOI: 10.1111/Bcp.12514 |
0.329 |
|
| 2014 |
Jin Y, Bies R, Gastonguay MR, Wang Y, Stockbridge N, Gobburu J, Madabushi R. Predicted impact of various clinical practice strategies on cardiovascular risk for the treatment of hypertension: a clinical trial simulation study. Journal of Pharmacokinetics and Pharmacodynamics. 41: 693-704. PMID 25326066 DOI: 10.1007/S10928-014-9394-9 |
0.561 |
|
| 2014 |
Li CH, Stratford RE, Velez de Mendizabal N, Cremers TI, Pollock BG, Mulsant BH, Remington G, Bies RR. Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. Journal of Translational Medicine. 12: 203. PMID 25142323 DOI: 10.1186/1479-5876-12-203 |
0.393 |
|
| 2014 |
Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Mimura M, Uchida H. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophrenia Research. 153: 184-8. PMID 24491908 DOI: 10.1016/J.Schres.2014.01.017 |
0.399 |
|
| 2014 |
Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies R, Grönte D, Remington G. Poster #S249 IS ONCE DAILY DOSING OF PERPHENAZINE CLINICALLY FEASIBLE? Schizophrenia Research. 153: S180. DOI: 10.1016/S0920-9964(14)70528-6 |
0.373 |
|
| 2013 |
Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophrenia Research. 150: 373-9. PMID 24028745 DOI: 10.1016/J.Schres.2013.08.033 |
0.434 |
|
| 2013 |
Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Journal of Clinical Psychopharmacology. 33: 682-5. PMID 23899638 DOI: 10.1097/Jcp.0B013E3182979A0A |
0.43 |
|
| 2013 |
Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A, Mimura M, Uchida H. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 45: 178-82. PMID 23727135 DOI: 10.1016/j.pnpbp.2013.05.010 |
0.381 |
|
| 2013 |
Li CH, Pollock BG, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, Sorisio D, Bies RR. Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study. Journal of Clinical Pharmacology. 53: 234-9. PMID 23436269 DOI: 10.1177/0091270012445793 |
0.409 |
|
| 2013 |
Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophrenia Bulletin. 39: 564-74. PMID 22290266 DOI: 10.1093/schbul/sbr189 |
0.401 |
|
| 2012 |
Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clinical Pharmacology and Therapeutics. 93: 345-51. PMID 23443753 DOI: 10.1038/Clpt.2012.263 |
0.512 |
|
| 2012 |
Wessels AM, Jin Y, Pollock BG, Frank E, Lange AC, Vrijens B, Fagiolini A, Kupfer DJ, Rucci P, Kepple G, Anderton J, Buttenfield J, Bies RR. Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' study. International Clinical Psychopharmacology. 27: 291-7. PMID 22990142 DOI: 10.1097/Yic.0B013E3283597678 |
0.607 |
|
| 2012 |
Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. Journal of Pharmacokinetics and Pharmacodynamics. 39: 393-414. PMID 22767341 DOI: 10.1007/S10928-012-9258-0 |
0.364 |
|
| 2012 |
Jin Y, Bies R, Gastonguay MR, Stockbridge N, Gobburu J, Madabushi R. Misclassification and discordance of measured blood pressure from patient's true blood pressure in current clinical practice: a clinical trial simulation case study. Journal of Pharmacokinetics and Pharmacodynamics. 39: 283-94. PMID 22569889 DOI: 10.1007/S10928-012-9250-8 |
0.554 |
|
| 2012 |
Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Therapeutic Drug Monitoring. 34: 182-7. PMID 22377743 DOI: 10.1097/FTD.0b013e3182489a6f |
0.463 |
|
| 2012 |
Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ. Resampling phase III data to assess phase II trial designs and endpoints. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2309-15. PMID 22287601 DOI: 10.1158/1078-0432.Ccr-11-1815 |
0.472 |
|
| 2012 |
Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 37: 182-7. PMID 22230651 DOI: 10.1016/J.Pnpbp.2011.12.013 |
0.4 |
|
| 2012 |
Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK, Pollock BG, Mulsant BH, Bies RR. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 20: 53-60. PMID 21422906 DOI: 10.1097/JGP.0b013e3182118318 |
0.428 |
|
| 2011 |
Feng Y, Gastonguay MR, Pollock BG, Frank E, Kepple GH, Bies RR. Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy. Neuropsychiatric Disease and Treatment. 7: 117-25. PMID 21552314 DOI: 10.2147/Ndt.S15921 |
0.443 |
|
| 2011 |
Poloyac SM, Empey KM, Rohan LC, Skledar SJ, Empey PE, Nolin TD, Bies RR, Gibbs RB, Folan M, Kroboth PD. Core competencies for research training in the clinical pharmaceutical sciences. American Journal of Pharmaceutical Education. 75: 27. PMID 21519417 DOI: 10.5688/Ajpe75227 |
0.538 |
|
| 2011 |
Bigos KL, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Molecular Psychiatry. 16: 620-5. PMID 21519338 DOI: 10.1038/mp.2011.38 |
0.536 |
|
| 2011 |
Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. Journal of Clinical Pharmacology. 51: 1587-91. PMID 21209243 DOI: 10.1177/0091270010387604 |
0.421 |
|
| 2010 |
Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. Journal of Clinical Psychopharmacology. 30: 683-7. PMID 21105282 DOI: 10.1097/Jcp.0B013E3181Fa05Bb |
0.425 |
|
| 2010 |
Lenze EJ, Goate AM, Nowotny P, Dixon D, Shi P, Bies RR, Lotrich FK, Rollman BL, Shear MK, Thompson PA, Andreescu C, Pollock BG. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. Journal of Clinical Psychopharmacology. 30: 672-7. PMID 21105279 DOI: 10.1097/Jcp.0B013E3181Fc2Bef |
0.388 |
|
| 2010 |
Han K, Capitano B, Bies R, Potoski BA, Husain S, Gilbert S, Paterson DL, McCurry K, Venkataramanan R. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrobial Agents and Chemotherapy. 54: 4424-31. PMID 20679503 DOI: 10.1128/Aac.00504-10 |
0.352 |
|
| 2010 |
Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. Journal of Clinical Pharmacology. 50: 73-80. PMID 19843655 DOI: 10.1177/0091270009343694 |
0.618 |
|
| 2010 |
Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, Müller DJ, Kennedy JL, Forgione RN, Kirshner M, Kepple G, Fagiolini A, Kupfer DJ, Bies RR. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. Journal of Clinical Pharmacology. 50: 62-72. PMID 19841156 DOI: 10.1177/0091270009337946 |
0.622 |
|
| 2009 |
Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gender Medicine. 6: 522-43. PMID 20114004 DOI: 10.1016/j.genm.2009.12.004 |
0.72 |
|
| 2009 |
Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B, Pollock BG, Mulsant BH, Bies RR. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Therapeutic Drug Monitoring. 31: 360-6. PMID 19349931 DOI: 10.1097/Ftd.0B013E31819C7037 |
0.455 |
|
| 2009 |
Jin Y, Pollock BG, Frank E, Florian J, Kirshner M, Fagiolini A, Kupfer DJ, Gastonguay MR, Kepple G, Feng Y, Bies RR. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. Journal of Clinical Pharmacology. 49: 176-84. PMID 19179296 DOI: 10.1177/0091270008327538 |
0.629 |
|
| 2009 |
Kamarck TW, Haskett RF, Muldoon M, Flory JD, Anderson B, Bies R, Pollock B, Manuck SB. Citalopram intervention for hostility: results of a randomized clinical trial. Journal of Consulting and Clinical Psychology. 77: 174-88. PMID 19170463 DOI: 10.1037/A0014394 |
0.484 |
|
| 2009 |
Pollock B, Forsyth C, Bies R. The critical role of clinical pharmacology in geriatric psychopharmacology. Clinical Pharmacology & Therapeutics. 85: 89-93. PMID 19037202 DOI: 10.1038/Clpt.2008.229 |
0.528 |
|
| 2008 |
Lenze EJ, Sheffrin M, Driscoll HC, Mulsant BH, Pollock BG, Dew MA, Lotrich F, Devlin B, Bies R, Reynolds CF. Incomplete response in late-life depression: getting to remission. Dialogues in Clinical Neuroscience. 10: 419-30. PMID 19170399 |
0.392 |
|
| 2008 |
Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Therapeutic Drug Monitoring. 30: 674-81. PMID 19057371 DOI: 10.1097/Ftd.0B013E31818B6B2F |
0.726 |
|
| 2008 |
Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. British Journal of Clinical Pharmacology. 66: 629-39. PMID 18771484 DOI: 10.1111/J.1365-2125.2008.03276.X |
0.394 |
|
| 2008 |
Frank E, Cassano GB, Rucci P, Fagiolini A, Maggi L, Kraemer HC, Kupfer DJ, Pollock B, Bies R, Nimgaonkar V, Pilkonis P, Shear MK, Thompson WK, Grochocinski VJ, Scocco P, et al. Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. Clinical Trials (London, England). 5: 253-61. PMID 18559415 DOI: 10.1177/1740774508091965 |
0.441 |
|
| 2008 |
Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G. Anticholinergic activity of 107 medications commonly used by older adults. Journal of the American Geriatrics Society. 56: 1333-41. PMID 18510583 DOI: 10.1111/j.1532-5415.2008.01737.x |
0.399 |
|
| 2008 |
Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 3221-5. PMID 18463627 DOI: 10.1038/Npp.2008.52 |
0.715 |
|
| 2008 |
Bigos KL, Chew ML, Bies RR. Pharmacokinetics in geriatric psychiatry. Current Psychiatry Reports. 10: 30-6. PMID 18269892 |
0.708 |
|
| 2008 |
Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology. 48: 157-65. PMID 18199892 DOI: 10.1177/0091270007310385 |
0.745 |
|
| 2006 |
Bigos KL, Bies RR, Pollock BG. Population pharmacokinetics in geriatric psychiatry. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 993-1003. PMID 17138806 DOI: 10.1097/01.JGP.0000224330.73063.6c |
0.749 |
|
| 2006 |
Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S, Gharabawi G. A model of anticholinergic activity of atypical antipsychotic medications. Schizophrenia Research. 88: 63-72. PMID 16928430 DOI: 10.1016/j.schres.2006.07.011 |
0.421 |
|
| 2006 |
Lotrich FE, Bies RR, Smith GS, Pollock BG. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. Journal of Psychopharmacology (Oxford, England). 20: 33-40. PMID 16785268 DOI: 10.1177/1359786806066044 |
0.478 |
|
| 2006 |
Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF, Bies RR. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British Journal of Clinical Pharmacology. 61: 558-69. PMID 16669849 DOI: 10.1111/J.1365-2125.2006.02629.X |
0.451 |
|
| 2006 |
Bies RR, Muldoon MF, Pollock BG, Manuck S, Smith G, Sale ME. A genetic algorithm-based, hybrid machine learning approach to model selection. Journal of Pharmacokinetics and Pharmacodynamics. 33: 195-221. PMID 16565924 DOI: 10.1007/S10928-006-9004-6 |
0.346 |
|
| 2006 |
Feng Y, Pollock B, Ferrell R, Kimak M, Reynoldsiii C, Bies R. PI-10CYP2D6 genotype and paroxetine pharmacokinetics in the elderly: A population pharmacokinetics analysis in depressed geriatric subjects Clinical Pharmacology & Therapeutics. 79. DOI: 10.1016/J.Clpt.2005.12.031 |
0.461 |
|
| 2005 |
Bies RR, Mulsant BH, Rosen J, Huber KA, Wilson NL, Kirshner MA, Pollock BG. Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. The American Journal of Geriatric Pharmacotherapy. 3: 87-91. PMID 16129385 DOI: 10.1016/j.amjopharm.2005.07.002 |
0.367 |
|
| 2005 |
Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology. 178: 268-75. PMID 15365685 DOI: 10.1007/S00213-004-2006-4 |
0.487 |
|
| 2005 |
Rea RS, Capitano B, Bigos K, Bies R, Smith R. Suboptimal Aminoglycoside Dosing In Critically Ill Patients.: 235-T Critical Care Medicine. 33. DOI: 10.1097/00003246-200512002-00603 |
0.7 |
|
| 2004 |
Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ, Pollock BG. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. Journal of Clinical Pharmacology. 44: 1352-9. PMID 15545305 DOI: 10.1177/0091270004269647 |
0.46 |
|
| 2003 |
Bies RR, Bigos KL, Pollock BG. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. The Journal of Gender-Specific Medicine : Jgsm : the Official Journal of the Partnership For Women's Health At Columbia. 6: 12-20. PMID 14513571 |
0.716 |
|
| 2003 |
Bies RR, Lotrich FE, Smith G, Muldoon M, Pollock BG. Pharmacokinetics of citalopram after IV infusion Clinical Pharmacology & Therapeutics. 73: P71-P71. DOI: 10.1016/S0009-9236(03)90620-5 |
0.385 |
|
| 2002 |
Bies RR, Gastonguay MR, Coley KC, Kroboth PD, Pollock BG. Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 696-705. PMID 12427578 DOI: 10.1097/00019442-200211000-00008 |
0.678 |
|
| Show low-probability matches. |